Compare Agilent Technologies Inc (A) vs Nike Inc (NKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Nike Inc — how do they compare? Agilent Technologies Inc trades at $129 (market cap $37.04B), while Nike Inc trades at $42.93 (market cap $63.99B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| A | NKE | |
|---|---|---|
Market Cap | $37.04B | $63.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $79.24 |
52-Week Low | $110.24 | $40.75 |
Enterprise Value | $38.59B | $66.00B |
Dividend Yield | 0.78% | 3.8% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Nike (NKE) trades at $43.34, down 1.7% on the day, with a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, but revenue declined to $46.31B in 2025 with net income falling to $3.22B. The stock shows strong profitability margins and a P/E of 20.64, while analysts maintain a consensus Buy rating with a $50.67 price target. Key support lies at $42, with resistance at $44.
Nike faces near-term headwinds from sluggish consumer demand and margin pressure, but its brand strength and digital direct-to-consumer strategy provide long-term upside potential. Risks include inventory challenges and economic sensitivity, yet institutional confidence remains with 48.6% analyst Buy ratings. The upcoming Q4 2026 earnings on June 30, 2026, will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
